PD-1 blockade enhances elotuzumab efficacy in mouse tumor models-Reference-Cited by-同舟云学术

PD-1 blockade enhances elotuzumab efficacy in mouse tumor models

Published:2017-05-08 Issue:12 Volume:1 Page:753-765
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Bezman Natalie A.¹,Jhatakia Amy¹,Kearney Alper Y.¹,Brender Ty¹,Maurer Mark¹,Henning Karla¹,Jenkins Misty R.²,Rogers Amy J.²,Neeson Paul J.²,Korman Alan J.¹,Robbins Michael D.³,Graziano Robert F.⁴

Affiliation:

1. Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA;

2. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;

3. Medical Oncology, Bristol-Myers Squibb, Princeton, NJ; and

4. Discovery Research, Bristol-Myers Squibb, Lawrenceville, NJ

Abstract

Key PointsThe combination of elotuzumab and an anti–PD-1 antibody leads to enhanced antitumor efficacy in mouse models. Enhanced antitumor activity is likely due to the promotion of tumor-infiltrating NK and T-cell activity.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/12/753/877200/advances004382.pdf

Reference51 articles.

1. Monoclonal antibodies for cancer immunotherapy;Weiner;Lancet,2009

2. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape;Ferris;J Clin Oncol,2010

3. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets;Clynes;Nat Med,2000

4. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies;Taylor;Curr Opin Immunol,2008

5. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy;Uchida;J Exp Med,2004

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exercise accelerates recruitment of CD8+ T cell to promotes anti-tumor immunity in lung cancer via epinephrine;BMC Cancer;2024-04-15

2. Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma;2024-03-11

3. Immune checkpoint inhibitors for multiple myeloma immunotherapy;Experimental Hematology & Oncology;2023-11-28

4. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond;Frontiers in Immunology;2023-07-18

5. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin;Scientific Reports;2023-03-29